Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-fibrinolytic drugs are used to prevent the breakdown of blood clots and are commonly used in surgeries to reduce bleeding. The Americas region has seen significant development in the anti-fibrinolytic drugs market in recent years.
Customer preferences: Customers in the Americas region have shown a growing preference for anti-fibrinolytic drugs due to their effectiveness in reducing bleeding during surgeries. With an aging population, there has been an increase in surgeries being performed, leading to a higher demand for these drugs. Additionally, the rise in the number of trauma cases has also contributed to the growth of the anti-fibrinolytic drugs market.
Trends in the market: The United States is the largest market for anti-fibrinolytic drugs in the Americas region, with a high demand for these drugs due to an increase in the number of surgeries being performed. The market is also seeing an increase in the use of tranexamic acid, a type of anti-fibrinolytic drug, in trauma cases. Brazil and Mexico are also emerging markets for anti-fibrinolytic drugs due to the rise in surgeries being performed in these countries.
Local special circumstances: In Brazil, the government has been investing in the healthcare sector, leading to an increase in the number of surgeries being performed. The country has also seen a rise in the number of trauma cases, leading to a higher demand for anti-fibrinolytic drugs. In Mexico, the rise in medical tourism has contributed to the growth of the anti-fibrinolytic drugs market, with an increasing number of patients traveling to the country for surgeries.
Underlying macroeconomic factors: The Americas region has a growing aging population, leading to an increase in the number of surgeries being performed. Additionally, the rise in the number of trauma cases has also contributed to the growth of the anti-fibrinolytic drugs market. The healthcare sector in the region has also been growing, with governments investing in healthcare infrastructure and facilities. These factors have led to a higher demand for anti-fibrinolytic drugs in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
